Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 5/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 4/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9187015 | 0.80 | BIRC2 (0.40) | BIRC2CHRM5CHRM3HSD17B10MAPT | |
| SCHEMBL8815561 | 0.80 | BIRC2 (0.40) | BIRC2HSD17B10MAPT | |
| SCHEMBL12195315 | 0.79 | BIRC2 (0.35) | BIRC2HSD17B10MAPT | |
| SCHEMBL15894887 | 0.77 | BIRC2 (0.38) | BIRC2HSD17B10MAPTCCR2KCNH2 | |
| SCHEMBL9186309 | 0.77 | BIRC2 (0.61) | BIRC2XIAP | |
| SCHEMBL14097349 | 0.77 | BIRC2 (0.41) | BIRC2HSD17B10MAPTXIAP | |
| SCHEMBL6100284 | 0.77 | BIRC2 (0.41) | BIRC2HSD17B10MAPT | |
| SCHEMBL20473764 | 0.75 | BIRC2 (0.34) | BIRC2HSD17B10MAPTSLC6A9 | |
| SCHEMBL18922120 | 0.74 | BIRC2 (0.43) | BIRC2CHRM5CHRM3HSD17B10MAPT | |
| SCHEMBL24296905 | 0.74 | BIRC2 (0.36) | BIRC2HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039845-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180085478-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085478-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS | FOLH1, KLK3, PHOSPHO1 | BIRC2 1902/4885CHRM5 4671/4885CHRM3 4379/4885 |
| US-10039845-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents | FOLH1, KLK3, PHOSPHO1 | BIRC2 1902/4885CHRM5 4671/4885CHRM3 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.